Business Monitor International


Brazil Pharmaceuticals & Healthcare Report

Published 29 May 2014

  • 163 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Brazil Pharmaceuticals & Healthcare Report

BMI View: The Brazilian pharmaceutical market will continue to be the most attractive to multinational pharmaceutical companies in Latin America. S trong government support, an improving regulatory regime and significant private healthcare growth mean that the market presents significant revenue-generating opportunities for drugmakers and healthcare service providers. However, multinationals will continue to face increasing drug pricing pressure and domestic competition .

Headline Expenditure Projections

  • Pharmaceuticals: BRL57.0bn (USD26.4bn) in 2013 to BRL61.8bn (USD25.8bn) in 2014; +8.5% in local currency terms and -2.4% in US dollar terms. Forecast revised upwards from Q214 due to changes to macroeconomic forecast.

  • Healthcare: BRL450.0bn (USD208.5bn) in 2013 to BRL496.7bn (USD207.0bn) in 2014; +10.4% in local currency terms and -0.7% in US dollar terms. Forecast revised upwards from Q214 due to changes to historical data.

Risk/Reward Rating: Brazil scores 62.7 in BMI's Pharmaceutical and Healthcare Risk/Reward Ratings (RRR), making it the third-most attractive pharmaceutical market in America. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected by this quarter's RRR scores.

Key Trends And Developments

  • In April 2014 representatives from universities, scientific research institutions and the pharmaceutical industry created the 'Alliance for Clinical Research in Brazil' to promote clinical research and reduce approval times.

  • In April 2014, the ANVISA office of pharmaceutical drug market regulation (CMED), fixed the average price increase of medicines to a maximum of 3.35% for 2014 - the lowest price increase approved by CMED in the last five years.

  • In March 2014 Bain Capital, a US-based private equity firm, invested BRL2bn (USD880mn) to acquire the Brazilian health insurance operator Grupo Notre Dame Intermedica (GNDI) from its founder Dr....

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecasts, USDmn (Brazil 2012-2018)
34
Table: Pharmaceutical Trade Data And Forecasts, BRLmn (Brazil 2012-2018)
35
Other Healthcare Data
36
Key Risks To BMI's Forecast Scenario
37
Macroeconomic Forecasts
38
Table: Brazil - Economic Activity
43
Industry Risk Reward Ratings
44
Americas Risk/Reward Ratings
44
Brazil Risk/Reward Ratings
50
Rewards
50
Risks
50
Market Overview
52
Industry Trends And Developments
53
Epidemiology
53
Rare Diseases
56
Compassionate Use Programmes
56
Healthcare Sector
57
Research & Development
61
Table: Brazilian Government's Partnership Deals With Multinationals
62
Biotechnology
65
Clinical Trials
72
Regulatory Development
74
Intellectual Property Regime
76
Counterfeit Drugs
79
Compulsory Licensing
80
Pricing Regime
81
Reimbursement Regime
84
OTC Regulations
87
Advertising
89
Protectionist Measures
89
Competitive Landscape
93
Table: Top 20 Pharmaceutical Companies In Brazil By Sales In 2010
93
Innovative Drugmakers
94
Generic Drugmakers
104
Table: Hypermarcas' Major Acquisitions, 2005-11
106
OTC Sector
108
Pharmaceutical Distribution Sector
109
Pharmaceutical Retail Sector
111
Company Profile
116
Ach-/Biosint-tica
116
EMS Sigma
120
Eurofarma
123
Medley
126
Crist-lia
129
Sanofi
132
Pfizer
136
Merck & Co
141
Novartis
145
GlaxoSmithKline
149
Table: GSK'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil
152
Roche
153
Demographic Forecast
157
Table: Brazil's Population By Age Group, 1990-2020 ('000)
158
Table: Brazil's Population By Age Group, 1990-2020 (% of total)
159
Table: Brazil's Key Population Ratios, 1990-2020
160
Table: Brazil's Rural And Urban Population, 1990-2020
160
Glossary
161
Methodology
163
Pharmaceutical Expenditure Forecast Model
163
Healthcare Expenditure Forecast Model
163
Notes On Methodology
164
Risk/Reward Ratings Methodology
165
Ratings Overview
166
Table: Pharmaceutical Risk/Reward Ratings Indicators
166
Indicator Weightings
167

The Brazil Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazilian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Brazil to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Brazilian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc